10 completed, 5 terminated, 2 withdrawn, 1 recruiting. 9 Phase 2, 6 Phase 1, 3 Not applicable, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 9 | Completed 8, Terminated 1 |
| Phase 1 | 6 | Terminated 2, Withdrawn 2, Completed 1, Recruiting 1 |
| Not applicable | 3 | Completed 1, Terminated 1, Unknown 1 |
| Phase 3 | 1 | Terminated 1 |
Follow Carcinoma, Non Small Cell Lung: new trials by email Literature Review of Carcinoma, Non Small Cell Lung trials Research Report on Carcinoma, Non Small Cell Lung
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study to Learn About the Study Medicine Called PF-08046876 in People With Advanced Solid Tumors PF-08046876, Pembrolizumab, Cisplatin - Advanced/Metastatic Solid Tumors, Bladder Cancer | Phase 1 | Recruiting | Pfizer | 540 | 2025-08-20 | 2026-10-13 |
| A Clinical Trial of PF-08046037 Alone or With Sasanlimab in Patients With Advanced or Metastatic Malignancies PF-08046037, sasanlimab - Carcinoma, Non Small Cell Lung, Carcinoma, Pancreatic Ductal | Phase 1 | Terminated | Pfizer | 8 | 2025-05-06 | 2026-04-23 |
| A Study Of PF-06263507 In Patients With Advanced Solid Tumors PF-06263507 - Neoplasms, Carcinoma, Non Small Cell Lung | Phase 1 | Terminated | Pfizer | 26 | 2013-08-08 | 2019-01-09 |
| Healthy Directions After Lung Surgery Pilot Lifestyle counseling - Carcinoma, Non Small Cell Lung | Not applicable | Completed | Dana-Farber Cancer Institute | 42 | 2012-09-01 | 2018-07-02 |
| Docetaxel +/- Suramin in 2nd Line Advanced Non-Small Cell Lung Cancer Docetaxel, Suramin - Carcinoma, Non Small Cell Lung | Phase 2 | Completed | University of Wisconsin, Madison | 80 | 2012-06-01 | 2020-05-12 |
| A Study of Pemetrexed and Gefitinib Versus Gefitinib in Non-Small Cell Lung Cancer (NSCLC) Gefitinib, Pemetrexed - Carcinoma, Non Small Cell Lung | Phase 2 | Completed | Eli Lilly and Company | 195 | 2012-02-01 | 2019-09-10 |
| TaxoteRe Plus Cisplatin Versus AlImta Plus Cisplatin in 1st Line Non-squamous Cell Type Lung Cancer Taxotere, Pemetrexed - Carcinoma, Non Small Cell Lung | Phase 3 | Terminated | Chonnam National University Hospital | 148 | 2011-07-01 | 2015-07-14 |
| Tarceva and AT-101 for Patients With Advanced Non-Small Cell Lung Cancer Tarceva plus AT-101 - Carcinoma, Non Small Cell Lung | Phase 1 | Withdrawn | University of Alabama at Birmingham | 2010-02-01 | 2015-05-08 | |
| Study of Pemetrexed Plus Cisplatin as First-line Therapy in Patients With Advanced Non-squamous NSCLC Pemetrexed/Cisplatin - Carcinoma, Non Small Cell Lung | Phase 2 | Terminated | Spanish Lung Cancer Group | 57 | 2010-01-01 | 2024-10-15 |
| Trial of ZD6474 and Faslodex in Non-Small Cell Lung Cancer ZD6474 (vandetanib), Faslodex (Fulvestrant) - Carcinoma, Non Small Cell Lung | Phase 1 | Withdrawn | University of Wisconsin, Madison | 2009-11-01 | 2015-10-02 | |
| Intra-patient Dose Escalation Study of Sorafenib in Advanced Non-small Cell Lung Cancer sorafenib - Carcinoma, Non Small Cell Lung | Phase 1 | Completed | University of Wisconsin, Madison | 24 | 2009-07-28 | 2019-11-15 |
| Computed Tomography (CT) Perfusion Imaging of Lung Cancer CT Perfusion - Carcinoma, Non Small Cell Lung | Not applicable | Terminated | University of Pittsburgh | 16 | 2009-06-01 | 2015-10-21 |
| Vorinostat and Bortezomib as Third-line Treatment in Advanced Non-small Cell Lung Cancer vorinostat, bortezomib - Carcinoma, Non Small Cell Lung | Phase 2 | Completed | University of Wisconsin, Madison | 18 | 2008-12-01 | 2019-12-13 |
| PF-00299804 As A Single Agent, In Patients With Advanced Non-Small Cell Lung Cancer Who Have Failed Chemotherapy And Erlotinib PF-00299804 - Carcinoma, Non Small Cell Lung | Phase 2 | Completed | Pfizer | 66 | 2008-04-29 | 2019-05-21 |
| Trial Of PF-00299804 In Patients With Advanced Refractory Lung Cancer PF-00299804 - Carcinoma, Non Small Cell Lung | Phase 2 | Completed | Pfizer | 55 | 2008-02-05 | 2020-10-19 |
| Safety and Efficacy Study of a New Chemotherapy Agent to Treat Non-small-cell Lung Cancer Sagopilone (BAY86-5302, ZK 219477) - Carcinoma, Non Small Cell Lung | Phase 2 | Completed | Bayer | 128 | 2005-08-01 | 2014-12-04 |
| Validation of Coregistered CT-PET Imaging in Determining Tumor Volume and Atelectasis in Patients With Operable Non-Small-Cell Lung Cancer and Tumor Associated Atelectasis CT-scan, PET-scan - Carcinoma, Non Small Cell Lung | Not applicable | Unknown | Radboud University Medical Center | 15 | 2004-06-01 | 2008-06-04 |
| Gemcitabine/Platinum Containing Regimens as Preoperative Chemotherapy for Patients With Non Small Cell Lung Cancer gemcitabine, carboplatin, cisplatin - Carcinoma, Non Small Cell Lung | Phase 2 | Completed | Eli Lilly and Company | 70 | 2001-09-01 | 2007-01-26 |
| Efficacy Trial of Gemcitabine Containing Regimens As Preoperative Chemotherapy in Non Small Cell Lung Cancer Gemcitabine, Carboplatin, Paclitaxel - Carcinoma, Non Small Cell Lung | Phase 2 | Completed | Eli Lilly and Company | 77 | 2001-06-01 | 2007-01-26 |
Carcinoma, Non-Small-Cell Lung (19) · Squamous Cell Carcinoma of Head and Neck (2) · Adenocarcinoma Of Esophagus (1) · Adenocarcinoma of Lung (1) · Breast Neoplasms (1) · Carcinoma, Pancreatic Ductal (1) · Carcinoma, Transitional Cell (1) · Esophageal Neoplasms (1) · Esophageal Squamous Cell Carcinoma (1) · Head and Neck Neoplasms (1) · Health Behavior (1) · Lung Neoplasms (1) · Melanoma (1) · Neoplasm Metastasis (1) · Neoplasms (1)
Bronchial Neoplasms (19) · Carcinoma, Bronchogenic (19) · Lung Diseases (19) · Neoplasms by Site (19) · Respiratory Tract Diseases (19) · Respiratory Tract Neoplasms (19) · Thoracic Neoplasms (19) · Lung Neoplasms (18) · Neoplasms (18) · Endocrine Gland Neoplasms (3) · Endocrine System Diseases (3) · Adenocarcinoma (2) · Carcinoma (2) · Carcinoma, Squamous Cell (2) · Digestive System Diseases (2)
Cisplatin (4) · Carboplatin (3) · Pemetrexed (3) · Docetaxel (2) · Gemcitabine (2) · dacomitinib (2) · Bortezomib (1) · Cytidine Triphosphate (1) · Erlotinib Hydrochloride (1) · Fulvestrant (1) · Gefitinib (1) · Magnetic Resonance Spectroscopy (1) · PF-06263507 (1) · Paclitaxel (1) · Sorafenib (1)
Pfizer (5) · University of Wisconsin, Madison (4) · Eli Lilly and Company (3) · Bayer (1) · Chonnam National University Hospital (1) · Dana-Farber Cancer Institute (1) · Radboud University Medical Center (1) · Spanish Lung Cancer Group (1) · University of Alabama at Birmingham (1) · University of Pittsburgh (1)
United States (10) · South Korea (3) · China (2) · Puerto Rico (2) · Spain (2) · Canada (1) · Germany (1) · Japan (1) · Netherlands (1) · Taiwan (1) · United Kingdom (1)
Tien Hoang, M.D. (2) · Anne M Traynor, M.D. (1) · Anne M Traynor, MD (1) · Francisco Robert, M.D. (1) · Jan Bussink, MD, PhD (1) · Mark A. Socinski, MD (1) · Mary E. Cooley, PhD, RN, FAAN (1) · Rafael Santana-Davila, MD (1) · Young-Chul Kim, MD, PhD (1)
PMID 23522488, PMID 24501009, PMID 25521398, PMID 27507876, PMID 28070718
2025 (2), 2005 (1), 2009 (1)